相关实验视频

Updated: Jan 12, 2026

Murine Prostate Micro-dissection and Surgical Castration

Murine Prostate Micro-dissection and Surgical Castration

Published on: May 11, 2016

通过促进PTEN表达,KDM3B抑制了抵抗割的前列腺癌细胞的增殖

Pengfei Zhang¹, Yifan Liu², Liangming Pan³

¹Department of Urology, The Second Affiliated Hospital of Jiaxing University, 1518 North Huancheng Road, Jiaxing, 314000, Zhejiang, China.

European journal of medical research

|November 7, 2025

概括

基因组脱甲基酶KDM3B通过增加PTEN表达来抑制割抵抗性前列腺癌 (CRPC) 细胞生长. 这一发现揭示了KDM3B作为晚期前列腺癌 (PCa) 的潜在瘤抑制剂.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
表观遗传学在表观遗传学中,表观遗传学是指表观遗传学.

背景情况:

抗割前列腺癌 (CRPC) 是前列腺癌 (PCa) 的晚期阶段.
对于CRPC进展的分子驱动因素还没有完全理解.
基因氨酸脱甲基酶 (KDMs) 影响基因表达和癌症的发展;KDM3B在CRPC中的作用尚不清楚.

研究的目的:

调查KDM3B在CRPC进展中的机制性作用.
为了确定KDM3B表达水平是否与PCa和CRPC阶段相关.

主要方法:

在临床PCa和CRPC组织和公共数据集中分析KDM3B表达.
在体外和体内测试 (CCK-8,殖民地形成) 来评估CRPC细胞增殖.
RT-PCR,Western Blot (WB) 和CCK-8测试将KDM3B活动与CRPC发育和PTEN表达联系起来.

主要成果:

在PCa和CRPC组织中,KDM3B表达显著下降.
减少的KDM3B抑制了CRPC细胞的增殖.
发现KDM3B可以上调PTEN表达,调节其对CRPC细胞增殖的影响.

结论:

通过增强PTEN表达,KDM3B在CRPC中充当瘤抑制剂.
KDM3B的机制涉及到PTEN的调节,影响CRPC细胞的增殖.
这些发现表明KDM3B是前列腺癌的潜在治疗点.

关键词:

抗化PCa (CRPC) 的使用方法细胞的增殖细胞的增殖.在KDM3B中,它是KDM3B.在这里,我们可以使用PTEN.前列腺癌 (PCa) 是一种癌症.

更多相关视频

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

Prostate Organoid Cultures as Tools to Translate Genotypes and Mutational Profiles to Pharmacological Responses

Prostate Organoid Cultures as Tools to Translate Genotypes and Mutational Profiles to Pharmacological Responses

Published on: October 24, 2019

相关概念视频

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

PI3K/mTOR/AKT Signaling Pathway

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...